Secukinumab promising for paediatric enthesitis-related arthritis and juvenile psoriatic arthritis
18 Jun 2021
byRoshini Claire Anthony
Treatment with the fully human anti-IL17 monoclonal antibody secukinumab resulted in fewer, and a longer time to, disease flares in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), results of the phase III JUNIPERA trial showed.
